Journal of Neurology

, 254:1306 | Cite as

Mary Broadfoot Walker (1888–1974)

  • J. D. Johnston


Prostigmin Physostigmine Periodic Paralysis General Medical Council Healthcare Product Regulatory Agency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Keesey JC (1998) Contemporary Opinions about Mary Walker. A shy pioneer of therapeutic neurology. Neurology 51:1433–1439PubMedGoogle Scholar
  2. 2.
    Johnston JD (2005) The contribution of Dr. Mary Walker towards myasthenia gravis and periodic paralysis whilst working in poor law hospitals in London. J Hist Neurosci 14(2):121–137CrossRefPubMedGoogle Scholar
  3. 3.
    Walker MB (1934) Treatment of myasthenia gravis with physostigmine. Lancet (i):1200–1201Google Scholar
  4. 4.
    Walker MB (MRCP) (1935) Case showing the effect of Prostigmin on myasthenia gravis. Proc Roy Soc Med 28(I):759–761PubMedGoogle Scholar
  5. 5.
    Walker MB (MD) (1938) Myasthenia gravis: a case in which fatigue of the forearm muscles could induce paralysis of extra-ocular muscles. Proc Roy Soc Med 31(II):722PubMedGoogle Scholar
  6. 6.
    Walker MB (1973) Some discoveries on myasthenia gravis: the background. Br Med J 1973(2):42–43CrossRefGoogle Scholar
  7. 7.
    Walker MB (1935) A contribution to the study of myasthenia gravis. MD thesis. Edinburgh UniversityGoogle Scholar
  8. 8.
    Aitken RS, Allott EN, Castleden LIM, Walker M (1937) Observations on a case of familial periodic paralysis. Clin Sci 3:47–57Google Scholar
  9. 9.
    KSM (1974) Mary Broadfoot Walker MD Edin., MRCP. Lancet (ii):1401–1402Google Scholar
  10. 10.
    PWR (1974) Dr. Mary Walker. Lancet (ii):1582Google Scholar

Copyright information

© Steinkopff-Verlag 2007

Authors and Affiliations

  1. 1.Medicines and Healthcare productsRegulatory Agency, Floor 11, Market TowersLondonUK

Personalised recommendations